The NICE has issued final draft guidance endorsing the use of CSL Vifor's Filspari (sparsentan) for primary IgA nephropathy.

The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their ...

The Trump administration’s budget reconciliation bill has passed the US House of Representatives by a wafer-thin single-vote ...

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

GSK has received approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab).

Aptar Digital Health has signed a licensing agreement with AstraZeneca for detecting CKD using the latter’s AI-driven ...

Sanofi has agreed to acquire Vigil Neuroscience in a $470m deal, nearly a year after investing an initial $40m in the company ...

Paratek Pharmaceuticals has completed the acquisition of Optinose, valued at almost $330m, broadening its commercial product ...

Explore Novotech CEO John Moller's insights on the company's global expansion, commitment to diversity, and innovative ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Eli Lilly and Company has received marketing authorisation from the Australian Therapeutic Goods Administration (TGA) for ...

UK biopharmaceutical companies saw a surge in venture financing for innovator drugs in 2024, with double the total deal value ...